My view is that just with cf33, we have ground breaking treatment. In the fullness of time if response rates continue to be seen, then we will see it as standard care.
My personal view however, is that if the IV results duplicate what we have seen with the IT, albeit at a larger dose to account for dilution in the blood stream before accessing the tumour micro environment, then this is a whole new level. In my view, this must by nature be a massive catalyst to our investment value.
My view is that just with cf33, we have ground breaking...
-
- There are more pages in this discussion • 5,749 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
